PainReform Ltd. (PRFX)

NASDAQ: PRFX · IEX Real-Time Price · USD
0.840
+0.007 (0.84%)
Aug 18, 2022 3:47 PM EDT - Market closed
0.84%
Market Cap 8.93M
Revenue (ttm) n/a
Net Income (ttm) -7.02M
Shares Out 10.63M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,469
Open 0.824
Previous Close 0.833
Day's Range 0.815 - 0.860
52-Week Range 0.624 - 3.470
Beta n/a
Analysts Buy
Price Target 3.06 (+264.3%)
Earnings Date Aug 15, 2022

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporat... [Read more...]

Industry Drug Manufacturers-Specialty & Generic
IPO Date Sep 1, 2020
Employees 4
Stock Exchange NASDAQ
Ticker Symbol PRFX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PRFX stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 264.29% from the latest price.

Price Target
$3.06
(264.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PainReform Provides Business Update for the Second Quarter of 2022

On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, Aug. 16, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of esta...

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today ann...

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on Marc...

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est...

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Opera...

TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est...

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

TEL AVIV, Israel, Dec. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of esta...

PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today

PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on ...

PainReform Provides Business Update for the Third Quarter of 2021

Reports continued progress towards commencing Phase 3 clinical trials

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

TEL AVIV, Israel, Oct. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of esta...

PainReform Provides Business Update for the Second Quarter of 2021

Shifting manufacturing and scale up operation to U.S.-based Contract Development and Manufacturing Organization for PRF-110 Shifting manufacturing and scale up operation to U.S.-based Contract Developme...

PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading

We're seeing lots of activity from penny stock PainReform (PRFX) on Wednesday despite a lack of news from the pharmaceutical company. The post PRFX Stock: 7 Things to Know About Pharmaceutical Company P...

PainReform Provides Business Update for the First Quarter of 2021

Reports continued progress towards start of Phase 3 trials Reports continued progress towards start of Phase 3 trials

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non...

HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

PainReform Announces $6.0 Million Private Placement

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...